A method of treating Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), a cardiomyopathy or a muscular traumatism in a subject includes administering to the subject certain ADP ribosylcyclase antagonist compounds, certain cyclic ADP ribose (cADPR) antagonist compounds, certain nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist compounds or a mixture of these compounds.

The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R.sub.1, R.sub.2, R.sub.3, X, Y and Z are as defined in any one of claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R.sub.3, for use in the treatment of cancer. ##STR00001##

Improved methods for treating hepatitis B (HB) in patients with (5S,5′S,8S,8′S,10aR,10a′R)-3,3′-(1,3-phenylenedisulfonyl)bis(N-benzhydryl-5-((S)-2-(methylamino)propanamido)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide) (Compound (I)) are disclosed herein. Dosing regimens of Compound (I) for the treatment of HBV infection are provided.

Improved methods for treating hepatitis B (HB) in patients with (5S,5′S,8S,8′S,10aR,10a′R)-3,3′-(1,3-phenylenedisulfonyl)bis(N-benzhydryl-5-((S)-2-(methylamino)propanamido)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide) (Compound (I)) are disclosed herein. Dosing regimens of Compound (I) for the treatment of HBV infection are provided.

Provided are compositions comprising a first heteroaryl compound and a second heteroaryl compound dissolved in an aqueous liquid. Also provided are methods of treating a patient that include orally administering such an aqueous liquid to a patient, for example, wherein the patient has been diagnosed with a mitochondrial depletion syndrome. Kits are provided that include the first heteroaryl compound, the second heteroaryl compound, and optionally instructions for dissolving the first heteroaryl compound and the second heteroaryl compound in an aqueous liquid and administering the solution to a patient.

Provided are compositions comprising a first heteroaryl compound and a second heteroaryl compound dissolved in an aqueous liquid. Also provided are methods of treating a patient that include orally administering such an aqueous liquid to a patient, for example, wherein the patient has been diagnosed with a mitochondrial depletion syndrome. Kits are provided that include the first heteroaryl compound, the second heteroaryl compound, and optionally instructions for dissolving the first heteroaryl compound and the second heteroaryl compound in an aqueous liquid and administering the solution to a patient.

The present invention relates to novel HSP27 inhibitors, in particular purine derivatives according to general formula (I) or (II) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP2.

The present invention relates to novel HSP27 inhibitors, in particular purine derivatives according to general formula (I) or (II) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP2.

The invention provides a combination comprising: (i) a compound of formula (I.sup.o): ##STR00001## or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and (ii) a compound which is SGI-110 ##STR00002## or a tautomer or a solvate or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions containing the combinations and medical uses of the combinations.

The invention provides a combination comprising: (i) a compound of formula (I.sup.o): ##STR00001## or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and (ii) a compound which is SGI-110 ##STR00002## or a tautomer or a solvate or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions containing the combinations and medical uses of the combinations.